Mutational profile of colorectal cancer cells in patients with multiple primary cancers.

N Natalya N. Timoshkina (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) D Dmitry Yu. Gvaldin (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) M Moez Eid (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) D Dema Alset (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) N Natalya Soldatkina (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) Y Yuri Gevorkyan (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) L Liubov Yu Vladimirova (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) A Aleksandr V. Shaposhnikov (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) A Alexander V. Snezhko (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) A Andrey A. Maslov (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) D Dmitriy A. Savchenko (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) D Dmitry Sergeevich Petrov (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) E Elena A. Dzhenkova (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) O Olga K. Bondarenko (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) A Andrey Dashkov (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) V Vladimir Kolesnikov (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) G Gennadiy V. Kaminskiy (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation) O Oleg Ivanovich Kit (National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation)

Abstract

e15538 Background: Colorectal cancer (CRC) is one of the three most common malignancies and a frequent component of multiple primary cancers (MPCs). The molecular mechanisms driving the development of MPCs remain incompletely understood. This study aimed to investigate the mutational landscape of CRC occurring within the context of MPCs. Methods: The study included 450 patients with single primary CRC (sCRC) and 62 patients with synchronous or metachronous MPCs involving CRC. DNA was isolated from formalin-fixed, paraffin-embedded tumor tissues. All samples were analyzed for KRAS , NRAS , and BRAF mutations, as well as microsatellite instability (MSI) status. A subset of MPCs cases underwent targeted high-throughput next-generation sequencing (NGS). Bioinformatics tools were used for data analysis. Results: No significant differences in gender, age, or histological type were observed between the MPCs and sCRC groups. The frequency of the KRAS G12A mutation was significantly higher in the MPCs group (17.7%, n = 11) compared to the sCRC group (p < 0.0001; OR = 15.96; 95% CI [5.66–44.98]). A relative predominance of MSI-high status was also found in the MPCs group (p < 0.04; OR = 2.32; 95% CI [1.004–5.37]). Targeted NGS of CRC samples from the MPCs cohort revealed 109 genetic variants across 16 of the 32 genes analyzed. The most commonly mutated genes were TP53 , KRAS , PIK3CA , APC , and BRAF , predominantly involving missense and nonsense mutations. Conclusions: This study demonstrates that CRC arising as part of MPCs has a distinct molecular profile, characterized by a higher prevalence of specific KRAS mutations and MSI-high status. These findings provide a basis for further research into the molecular pathogenesis of MPCs, which may inform the development of improved treatment and surveillance strategies.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

N

Natalya N. Timoshkina

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

D

Dmitry Yu. Gvaldin

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

M

Moez Eid

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

D

Dema Alset

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

N

Natalya Soldatkina

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

Y

Yuri Gevorkyan

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

L

Liubov Yu Vladimirova

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

A

Aleksandr V. Shaposhnikov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

A

Alexander V. Snezhko

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

A

Andrey A. Maslov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

D

Dmitriy A. Savchenko

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

D

Dmitry Sergeevich Petrov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

E

Elena A. Dzhenkova

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

O

Olga K. Bondarenko

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

A

Andrey Dashkov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

V

Vladimir Kolesnikov

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

G

Gennadiy V. Kaminskiy

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

O

Oleg Ivanovich Kit

National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation